Multicenter, open-label, phase 1 study of DSP-7888 Dosing Emulsion (DSP-7888) in patients with advanced malignancies

被引：0
|
作者：
Groves, Morris [2 ]
Hansen, Aaron [3 ]
Harb, Wael [4 ]
Curtis, Kelly [5 ]
Koga-Yamakawa, Erina [6 ]
Origuchi, Makoto [7 ]
Li, Zhonggai [7 ]
Iglesias, Jose [7 ]
Shaib, Walid [8 ]
Spira, Alexander [1 ]
机构：
[1] Virginia Canc Specialists, Fairfax, VA USA
[2] Texas Oncol Austin Midtown, Austin, TX USA
[3] UHN Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Horizon Oncol Res LLC, Lafayette, IN USA
[5] Syneos Hlth, Phoenix, AZ USA
[6] Sumitomo Dainippon Pharma Co Ltd, Cambridge, MA USA
[7] Boston Biomed Inc, Cambridge, MA USA
[8] Emory Univ, Atlanta, GA 30322 USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P355
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies
    Alexander Spira
    Aaron R. Hansen
    Wael A. Harb
    Kelly K. Curtis
    Erina Koga-Yamakawa
    Makoto Origuchi
    Zhonggai Li
    Bella Ertik
    Walid L. Shaib
    Targeted Oncology, 2021, 16 : 461 - 469
  • [2] Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies
    Spira, Alexander
    Hansen, Aaron R.
    Harb, Wael A.
    Curtis, Kelly K.
    Koga-Yamakawa, Erina
    Origuchi, Makoto
    Li, Zhonggai
    Ertik, Bella
    Shaib, Walid L.
    TARGETED ONCOLOGY, 2021, 16 (04) : 461 - 469
  • [3] Phase 1/2 study evaluating the safety and efficacy of DSP-7888 dosing emulsion in myelodysplastic syndromes
    Ueda, Yasunori
    Usuki, Kensuke
    Fujita, Jiro
    Matsumura, Itaru
    Aotsuka, Nobuyuki
    Sekiguchi, Naohiro
    Nakazato, Tomonori
    Iwasaki, Hiromi
    Takahara-Matsubara, Mariko
    Sugimoto, Saori
    Goto, Masashi
    Naoe, Tomoki
    Kizaki, Masahiro
    Miyazaki, Yasushi
    Aakashi, Koichi
    CANCER SCIENCE, 2022, 113 (04) : 1377 - 1392
  • [4] PHASE 1/2 STUDY OF DSP-7888 IN PEDIATRIC PATIENTS WITH MALIGNANT GLIOMA
    Fujisaki, Hiroyuki
    Hashii, Yoshiko
    Terashima, Keita
    Goto, Hiroaki
    Horibe, Keizo
    Sugiyama, Kazuhiko
    Watanabe, Akinobu
    Sugimoto, Saori
    Yanagisawa, Takaaki
    Kikuta, Atsushi
    Kawamoto, Hiroshi
    Hashimoto, Naoya
    Hara, Junichi
    NEURO-ONCOLOGY, 2018, 20 : 202 - 202
  • [5] A randomized, multicenter phase 2 study of DSP-7888 dosing emulsion in combination with bevacizumab (Bev) versus Bev alone in patients with recurrent or progressive glioblastoma.
    De Groot, John Frederick
    Cloughesy, Timothy Francis
    Pitz, Marshall W.
    Narita, Yoshitaka
    Nonomura, Takeshi
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] A phase Ib/II, multicenter, open-label study of DSP-7888 dosing emulsion in combination with immune checkpoint inhibitors (CPI) nivolumab or pembrolizumab in adult patients (pts) with advanced solid tumors, including platinum-resistant ovarian cancer (PROC).
    Origuchi, Makoto
    Korth, Chris
    Li, Zhonggai
    Braendle, Edgar E.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Mechanism of action of DSP-7888 (adegramotide/nelatimotide) Emulsion, a peptide-based therapeutic cancer vaccine with the potential to turn up the heat on non-immunoreactive tumors
    Suginobe, Natsuko
    Nakamura, Megumi
    Takanashi, Yosuke
    Ban, Hitoshi
    Gotoh, Masashi
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (02): : 396 - 407
  • [8] Mechanism of action of DSP-7888 (adegramotide/nelatimotide) Emulsion, a peptide-based therapeutic cancer vaccine with the potential to turn up the heat on non-immunoreactive tumors
    Natsuko Suginobe
    Megumi Nakamura
    Yosuke Takanashi
    Hitoshi Ban
    Masashi Gotoh
    Clinical and Translational Oncology, 2023, 25 : 396 - 407
  • [9] DSP-7888, a Novel Cocktail Design of WT1 Peptide Vaccine, and Its Combinational Immunotherapy with Immune Checkpoint-Blocking Antibody Against PD-1
    Goto, Masashi
    Nakamura, Megumi
    Suginobe, Natsuko
    Takasu, Hideo
    Takanashi, Yosuke
    Ban, Hitoshi
    Li, Chiang J.
    BLOOD, 2016, 128 (22)
  • [10] A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
    Zonder, Jeffrey A.
    Mohrbacher, Ann F.
    Singhal, Seema
    van Rhee, Frits
    Bensinger, William I.
    Ding, Han
    Fry, John
    Afar, Daniel E. H.
    Singhal, Anil K.
    BLOOD, 2012, 120 (03) : 552 - 559
12345